Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.

Trial Profile

An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Epstein-Barr virus vaccine (Primary) ; Ibrutinib (Primary)
  • Indications B-cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms TREBL-1
  • Most Recent Events

    • 21 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top